EU/US Trade US tariffs and MFN pricing threaten pharma investment and access in Europe Rising uncertainty driven by US tariffs and proposed “most-favoured nation” pricing is prompting pharmaceutical companies to delay investment and product launches in Europe
Inside EU Health Inside EU Health: Alarming report on mental health of healthcare workers - tobacco taxation discussions kick off Inside EU Health: Spy scandal; tobacco discussions kick off; Healthcare workforce on the edge; another Trump tirade
